Akebia Therapeutics AKBA 深 沪
等待开盘 11-03 09:30:00 美东时间
2.21
+0.110
+5.24%
华盛通- 最 高2.23
- 今 开2.11
- 成交量 611.23万股
- 最 低 2.07
- 昨 收 2.10
- 总市值 5.86亿
- 52周最高 4.0787
- 市盈率 静 --
- 换手率 2.31%
- 52周最低 1.52
- 委 比 -50.88%
- 总股本 2.65亿
- 历史最高 31.00
- 量 比 0.67
- 振 幅 7.62%
- 历史最低 0.241
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
泰恩康1.1类创新药CKBA治疗阿尔兹海默症的创新研究成果登上国际顶刊《Natu...
2025年10月29日，泰恩康FIC创新小分子CKBA发明人、上海交通大学医学院附属第一人民医院王宏林团队在国际顶级期刊《Nature Aging》（专注老龄化...
10-29 19:51
Akebia Therapeutics shares are trading lower after the company said it will not initiate the VALOR trial following a lack of alignment with the FDA on trial design for Vafseo in CKD non-dialysis patients.
Akebia Therapeutics shares are trading lower after the company said it will not...
10-29 04:35
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
<p>Akebia Therapeutics announced it will not initiate the VALOR clinical trial for vadadustat to treat anemia in late-stage CKD patients not on dialysis, following feedback from the U.S. FDA. The FDA indicated the trial would require a significantly larger patient population, more time, and higher costs. Akebia is disappointed but believes this decision aligns with shareholders' interests. The company remains committed to making Vafseo (vadadusta...
10-28 20:30
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Akebia Therapeutics will present data on Vafseo® (vadadustat) at ASN Kidney Week 2025, sharing insights on its clinical benefits, dosing, and real-world studies. The research includes a win odds analysis comparing vadadustat with darbepoetin alfa for CKD-related anemia, as well as posters on dosing recommendations and ongoing trials like VOICE and VOCAL. The company emphasizes its commitment to advancing understanding of Vafseo and providing evid...
10-20 12:08
Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics executives will participate in two investor conferences in September: the Wells Fargo Healthcare Conference on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. A webcast of each presentation will be available on Akebia’s website post-conference.
08-28 12:00
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Akebia Therapeutics and Innovative Renal Care (IRC) announce the broad availability of Vafseo (vadadustat) for treating anemia in chronic kidney disease (CKD) patients on dialysis across IRC's over 230 US clinics. Approved by the FDA in March 2024, Vafseo is now accessible to thousands of IRC patients, supported by standardized treatment protocols. IRC's Chief Medical Officer, Dr. Geoffrey Walker, emphasizes their patient-centered approach throug...
08-21 12:00
Akebia Therapeutics shares are trading lower following the release of its Q2 financial results.
Akebia Therapeutics shares are trading lower following the release of its Q2 fi...
08-07 21:01
Akebia Therapeutics Q2 Sales $62.472M Beat $47.637M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $62.472 million which beat the analyst consensus estimate of $47.637 million by 31.14 percent. This is a 43.13 percent increase over sales of $43.648 million
08-07 19:03
